• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 28th February 2022

Rare Disease Day 2022

World Rare Disease Day aims to raise awareness of rare diseases and the impact they can have on patients. This blog explores OHE’s contributions to research into rare diseases and orphan medicines. World Rare Disease Day is celebrated on the…

_DSC0022
Nadine Henderson
Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Rare-Disease-Day-tiny

World Rare Disease Day aims to raise awareness of rare diseases and the impact they can have on patients. This blog explores OHE’s contributions to research into rare diseases and orphan medicines.

World Rare Disease Day is celebrated on the last day of February 28th or 29th in a leap year (the rarest day) to raise awareness of rare diseases and the impact they can have upon patients. The European Medicines Agency defines rare diseases as life-threatening or chronically debilitating conditions that have a prevalence of fewer than 5 cases per 10,000 population. Despite the low numbers of persons with any specific disease, rare diseases occur in up to 4% of births and 6-8% of the population in the EU; this equates to around 27-36 million people. Although rare diseases are individually rare, they are collectively common. Furthermore, 72% of rare diseases are genetic, meaning that they disproportionately affect children.

Treatments for many rare conditions include the use of medicines; these medicines are referred to as orphan medicines. New innovative treatments are continually being developed, but there are a number of economic and ethical challenges in the development and evaluation of medicines for these conditions that are distinct from those faced by medicines for more common conditions. These challenges are discussed in an OHE Consulting Report, particularly in the context of NICE’s appraisal of rare and ultra-rare conditions. We also considered to what extent standard appraisal processes are appropriate for ultra-orphan medicines, with a deep dive into NICE’s Highly Specialised Technologies pathway. Further research was conducted in this area, in which we developed case studies to describe these challenges and better understand the intricacies of the NICE appraisal process. We found a flexible and pragmatic approach towards uncertainty; these positive examples include consideration of bespoke statistical modelling, expert testimony, and/or the use of real-world evidence. Less positive examples were also observed, especially around inflexible consideration of uncertainties inherent around ultra-rare conditions.

The challenges associated with evaluating orphan medicines are demonstrated by the high degree of variability in access to orphan medicines across Europe. A recent analysis by OHE explored the reimbursement rates of 215 orphan medicines in 15 European countries from the introduction of Regulation No 141/2000 on Orphan Medicines in 2000 to the end of 2019. We observed substantial variation in the levels and speed of national reimbursement of orphan medicines. We found that Germany had the highest level of coverage, with 91% of orphan medicines being reimbursed. The three countries with the lowest reimbursement rate were Poland, Hungary and Norway (all below 30%).

OHE has also carried out research into the role of pharmaceutical innovation in the development of orphan medicines. In collaboration with EFPIA, we developed case studies that illustrate the specific drivers and barriers in developing medicines for rare diseases. We found that innovation requires hard work, sustained investment, partnership between innovators and regulators, and often, a bit of luck to unlock patient benefit.

We recently hosted a Masterclass exploring innovation for small populations, tackling the issues of generating the right incentives to stimulate research and development into new therapeutic solutions for rare diseases whilst also managing concerns around health system affordability. The Masterclass will soon be available on-demand via the OHE website, where you can download the presentations from OHE experts and other industry thought-leaders on the topic. Email events@ohe.org for further information.

 

  • Health Technology Assessment…
  • Value, Affordability, and…
  • Events

Related Insights

Eye-Disease Gene-Therapies blog
  • Insight
  • February 2023

Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?

Read more
Fishing on the lake at sunset. Fishing background.
  • Insight
  • February 2023

Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges

Read more
G7Antibiotics_blog_featuredimage
  • Insight
  • December 2022

G7 Investments in New Antibiotics Would Pay Off – For Everyone

Read more
jacek-dylag-IiQXLbTTQCw-unsplash-scaled-1
  • Insight
  • December 2022

ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!